Ana Sayfa | Dergi Hakkında | Yayın Kurulu | Bilimsel Danışma Kurulu | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | İletişim  
2017, Cilt 31, Sayı 3, Sayfa(lar) 165-172   
OUR ANTI-IGE (OMALIZUMAB) EXPERIENCE IN SEVERE ALLERGIC ASTHMA: 1ST YEAR EXPERIENCE
Ferda BİLGİR1, Bilge ÖZDEMİR2, Papatya DEĞİRMENCİ3, Bahadır DEDE4, Cengiz KIRMAZ5
1İzmir Katip Çelebi Üniversitesi Tıp Fakültesi Atatürk Eğitim ve Araştırma Hastanesi, Allerji ve İmmunoloji, İzmir, Türkiye
2Manisa Devlet hastanesi, Allerji ve İmmunoloji Kliniği, Manisa, Türkiye
3Tepecik Eğitim ve Araştırma Hastanesi, Allerji ve İmmunoloji Kliniği, İzmir, Türkiye
4Muğla İl Sağlık Müdürlüğü, Halk Sağlığı Müdürlüğü, Muğla, Türkiye
5Celal Bayar Üniveristesi Tıp Fakültesi, Allerji ve İmmunoloji Bilim Dalı, Manisa, Türkiye
Keywords: Asthma, omalizumab, allergy

Aim: Anti-IgE (omalizumab) therapy is known to be effective and useful in moderate to severe allergic asthma without response to standard treatments. This study aimed to share the data of our allergic asthmatic patients with omalizumab treatment.

Material and Methods: The records and data sheets of 23 patients with severe allergic asthma who underwent omalizumab treatment were retrospectively reviewed in our clinic. Sensitivity to allergen was detected by skin prick test. Serum total IgE, Astma Control Test, number of medications used, urgent admission, FEV1, FEV1 / FVC values were compared before and after omalizumab treatment.

Results: The mean age was 45.78 ± 10.71 years and the mean time of ilness of the patients were 13.69 ± 9.04 years. Of the 23 patients, 69.6% were female (n = 16). In addition to asthma, 65.2% of patients had allergic rhinitis, 34.8% had urticaria, 13% had drug allergy, 8.7% had food allergy, and 4.3% had latex allergies. House dust mite sensitivities were 78.3%, house dust mite + other inhaled allergen sensitivities were 21.7%. The number of asthma medications, serum total IgE and FEV1 / FVC decreased (P <0.05) and asthma control test scores increased (P <0.05) at the end of the 1st year of omalizumab treatment.

Conclusion: It has been shown that omalizumab treatment is effective and safe and well tolerated in our patients. We think that omalizumab treatment is useful in patients with severe allergic asthma who can not be controlled by standard treatments.